Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

VIR

Vir Biotechnology (VIR)

Vir Biotechnology Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:VIR
日付受信時刻ニュースソース見出しコード企業名
2024/06/1305 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/06/0519 : 04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
2024/06/0518 : 30Business WireTobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentNASDAQ:VIRVir Biotechnology Inc
2024/06/0401 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/06/0400 : 57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/06/0103 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/06/0103 : 42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/05/3005 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
2024/05/3005 : 05Business WireVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
2024/05/2921 : 05Business WireVir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical OfficerNASDAQ:VIRVir Biotechnology Inc
2024/05/2405 : 05Business WireVir Biotechnology to Host 2024 Annual Meeting of StockholdersNASDAQ:VIRVir Biotechnology Inc
2024/05/2221 : 05Business WireMultiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024NASDAQ:VIRVir Biotechnology Inc
2024/05/2121 : 17Business WireVir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024NASDAQ:VIRVir Biotechnology Inc
2024/05/1505 : 05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VIRVir Biotechnology Inc
2024/05/0305 : 05Business WireVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
2024/05/0105 : 05Business WireVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024NASDAQ:VIRVir Biotechnology Inc
2024/04/1821 : 00Business WireVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsNASDAQ:VIRVir Biotechnology Inc
2024/04/1205 : 30Business WireVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024NASDAQ:VIRVir Biotechnology Inc
2024/03/0522 : 05Business WireVir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of ScheduleNASDAQ:VIRVir Biotechnology Inc
2024/02/2709 : 34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/02/2709 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/02/2709 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/02/2709 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/02/2706 : 27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRVir Biotechnology Inc
2024/02/2706 : 10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRVir Biotechnology Inc
2024/02/2322 : 05Business WireVir Biotechnology to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:VIRVir Biotechnology Inc
2024/02/2306 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
2024/02/2306 : 05Business WireVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
2024/02/2106 : 33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
2024/02/2106 : 30Business WireVir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical OfficerNASDAQ:VIRVir Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:VIR

最近閲覧した銘柄

Delayed Upgrade Clock